For example, in NSCLC, several ICIs are currently used in all treatment lines in PD-L1 expressing cases, with unquestionable survival advantages certified in both clinical trials [27,28] and large real-life studies; in a recent nationwide real-world study performed in Denmark, the authors found that three-year overall survival tripled from 6% to 18% after implementation of immunotherapy [29]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.